Who is the CEO of Neovacs S.A.?

Mr. Hugo Brugiere M.Sc. is a business executive who currently serves as the CEO of Neovacs S.A..

What is the Revenue Growth of Neovacs S.A.?

Revenue growth data for Neovacs S.A. is currently unavailable.

What is Neovacs S.A. operating Margin?

Neovacs S.A. operating margin is -2322.07% which shows how much profit ALNEV.PA earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does Neovacs S.A. operate?

Neovacs S.A. falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is Neovacs S.A. revenue growth?

Revenue growth data for Neovacs S.A. is currently unavailable.

What is the IPO date for Neovacs S.A. stock?

The ALNEV.PA IPO is 2010-04-21.

Neovacs S.A.

ALNEV.PA•EURONEXT

HealthcareBiotechnology

$0.004

$-0.00(-14.29%)

Neovacs S.A. (ALNEV.PA) Stock Overview

Explore Neovacs S.A.’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for ALNEV.PAStats details for ALNEV.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for ALNEV.PAAnalyst Recommendations details for ALNEV.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

CEO

Mr. Hugo Brugiere M.Sc.

Employees

Headquarters

3-5, Impasse Reille, Paris

Founded

2010